Stockreport

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis [Yahoo! Finance]

Rein Therapeutics, Inc.  (RNTX) 
PDF Trial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and promote repair AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Th [Read more]